Researchers at a WuXi AppTec site in Philadelphia. (Credit: WuXi)

WuXi be­came a crit­i­cal part­ner to bio­phar­ma com­pa­nies. They’re not ready if the US cracks down

It’s hard to dis­en­tan­gle WuXi AppTec’s rise from Chi­na’s. Over the last two decades, the Shang­hai-based com­pa­ny grew from noth­ing in­to a re­search su­per­store for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.